Literature DB >> 11336618

The current status of antihypertensive treatments: into the new millennium.

T C Hardman, M W Lunnon.   

Abstract

In this short review, we present a historical perspective of the treatment of hypertension, highlight some current issues and look to the possible future of antihypertensive therapy. The distribution of blood pressure within the population adopts a continuous, albeit somewhat skewed, distribution, so what constitutes hypertension? Conventionally, the disease has been defined as a level of blood pressure >> 140/90 mmHg. Accepting this 'arbitrary' definition infers that approximately one quarter of the adult population in the US are hypertensive [1]. This has significant implications in terms of the impact upon public health. We know that treatment of hypertension can prevent the serious consequences of cardiovascular disease: stroke, myocardial infarction (MI), heart failure and renal disease. Thus, it is important that raised blood pressure is both detected and effectively lowered. To what level should blood pressure be reduced. Conventionally, a level of 120/80 mmHg has been used to define normotension but there are indications that under certain circumstances this should not be the target. The question also arises as to whether it matters how blood pressure is treated. The choice of agent may ultimately depend upon the presence of any concomitant condition and risk factors. Recent trial evidence has concluded that therapy selected to treat raised blood pressure should take into account the overall cardiovascular risk profile of the patient [2].

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11336618     DOI: 10.1517/14656566.2.5.731

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  1 in total

1.  Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure.

Authors:  Alison Oliveto; Michael Mancino; Nichole Sanders; Christopher Cargile; J Benjamin Guise; Warren Bickel; W Brooks Gentry
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.